Expert Interviews

Real-world data show tear film and Schirmer improvements with two preservative-free dry eye drops at ESCRS 2026.

Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.

Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.

A VR lens simulator used at InVision Eye Care lifted premium IOL conversion rates from 30%-35% to the mid-40s

Ashraf Ahmad, MD, explains what tear breakup time testing shows and why results vary between clinic visits.

Dante Pieramici, MD, on how a sustained-release TKI dosed every six months could cut clinic volume, ease treatment burden, and protect patients who otherwise disappear from care.

Jonathan Gloth, MD, discusses how a dual Tie2/VEGF mechanism could reduce injection burden and the consequences of missed doses in wet AMD.

John W. Kitchens, MD, discusses patient selection for geographic atrophy treatment, counseling approaches, and emerging therapies including a C1q inhibitor and cell-based options.

Amy Zhang, MD, discusses coverage barriers to home IOP monitoring, a surgical ergonomics habit for early-career surgeons, and glaucoma's role in burnout.

At WIO 2026, Durga Borkar, MD, discussed DAVIO2 trial results for EYP-1901 in wet AMD.

Dante Pieramici, MD, discusses EYP-1901, a sustained-delivery tyrosine kinase inhibitor targeting VEGF, PDGF, and IL-6 JAK/STAT signaling, in the phase 3 COMO and CAPRI diabetic macular edema trials.

Dante Pieramici, MD, breaks down the phase 3 COMO and CAPRI trials of EYP-1901 (Duravyu), an insert designed to ease treatment burden in diabetic macular edema.

Amy Zhang, MD, on why self-care alone won't fix physician burnout and what health systems need to address instead.

Amy Zhang, MD, on the ergonomic habits and equipment changes that protect ophthalmic surgeons' careers long-term.

25.5% of patients labeled with MacTel2 didn't meet diagnostic criteria, most often due to cystic OCT changes and telangiectatic vessels mistaken for the disease.

In this Q&A from EDES 2026 in Milan, Piotr A. Woźniak, MD, PhD, discusses his real-world evidence study on a dry eye lubricating drop, including its effects on tear film stability.

Capsulotomy size may not be refractive neutral: a larger opening shifted the IOL about 120 µm posteriorly in thin lenses and anteriorly in thick ones in a paired-eye study.

Stuart Therapeutics presented preclinical data at OIS Retina 2026 on a non-gene-specific collagen mimetic peptide that preserved retinal thickness and visual function in 2 mouse models of inherited retinal disease.

Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.

A single vorolanib intravitreal insert extended time to supplemental anti-VEGF injection vs aflibercept in previously treated DME at 24 weeks in phase 2 VERONA; pivotal phase 3 trials COMO and CAPRI are now underway.

A University of Chicago-led ASRS 2026 poster explores how large language and vision-language models could help retina specialists manage imaging, records, and clinical trial matching—without replacing physician judgment.

At ASRS 2026, the dual inflammasome inhibitor K8 slowed geographic atrophy lesion growth by up to 54% over 6 months in a phase 2 trial and showed a visual acuity advantage in eyes with extrafoveal lesions, with no drug-related serious adverse events.

Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central serous chorioretinopathy (CSCR)

Carl C. Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, with strong safety through 4 years of follow-up.

In a first-in-human Phase 1 trial, a single TH103 injection improved vision and reduced fluid in treatment-naive wet AMD, with roughly a third of patients needing no retreatment through 6 months.

5-year OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained aflibercept expression and no new safety signals, in a high-need population with nAMD.

Real-world data presented at ASRS 2026 show pegcetacoplan slowed photoreceptor and RPE loss in geographic atrophy, with a greater treatment effect in eyes with concurrent neovascular AMD.

A wider partial-total ellipsoid zone gap on OCT predicted faster total EZ loss and geographic atrophy in intermediate AMD—pointing to a biomarker for trial enrichment.